Let’s dig into the relative performance of CRA (NASDAQ:CRAI) and its peers as we unravel the now-completed Q2 business process outsourcing & consulting earnings season.

CRA International’s second quarter saw revenue and non-GAAP earnings per share both surpass Wall Street expectations, but the market responded with some caution. Management attributed the company’s performance to double-digit growth across several core practices, including Energy, Life Sciences, and Forensic Services, as well as strong contributions from Antitrust & Competition Economics. CEO Paul Maleh pointed out that both North American and international operations contributed to the top-line

Record revenue of $210.8 million drives guidance raise and first headcount gain in two years.

CRAI's 20% three-month gain is backed by broader demand, a stronger project pipeline and higher fiscal 2026 revenue guidance, but costs remain a drag.

CRAI's broader demand and raised fiscal 2026 revenue outlook bolster growth, but margin pressure, cash use and leverage keep the investment case balanced.

What CRA International’s latest earnings and capital moves mean for investors CRA International (CRAI) has been active on several fronts recently. The company reported second quarter and first half 2026 earnings, refinanced and expanded its credit facility, affirmed its dividend, and continued buying back shares. See our latest analysis for CRA International. CRA International’s share price has pulled back in the short term, with a 1 day share price return of down 4.05% and a 7 day return of...

Economic consulting firm CRA International (NASDAQ:CRAI) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 12.8% year on year to $210.8 million. Its non-GAAP profit of $2.16 per share was 0.6% above analysts’ consensus estimates.

Moby summary of CRA International, Inc.'s Q2 2026 earnings call

Charles River Associates (NASDAQ:CRAI) reported record second-quarter revenue and profit metrics, citing broad-based growth across its consulting portfolio, higher utilization and continued strength in its pipeline of new projects. Revenue for the second quarter of fiscal 2026 was $210.8 million, u

CRA (CRAI) delivered earnings and revenue surprises of +1.89% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Economic consulting firm CRA International (NASDAQ:CRAI) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 12.8% year on year to $210.8 million. Its non-GAAP profit of $2.16 per share was 0.6% above analysts’ consensus estimates.

ISG (III) delivered earnings and revenue surprises of +11.11% and +4.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Hackett Group (HCKT) delivered earnings and revenue surprises of 0.00% and -0.81%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Huron Consulting (HURN) delivered earnings and revenue surprises of +15.49% and +4.11%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Riverwater Partners, an investment management company, released its “Micro Opportunities Strategy” Q2 2026 investor letter. A copy of the letter is available to download here. In Q2 2026, the Micro Opportunities strategy underperformed the Russell Microcap Index, despite a positive absolute result. The benchmark performed well during a speculative period for micro caps. Over the […]

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.

In July 2026, BriaCell Therapeutics Corp. announced it had engaged Charles River Associates (CRA International) and Kaleio, Inc. to support commercial strategy, market access evaluation, and brand planning for Bria-IMT, its investigational metastatic breast cancer therapy currently in a pivotal Phase 3 trial. This engagement highlights how CRA International’s specialized healthcare and market access expertise is being tapped early in the oncology commercialization process, underscoring its...

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Investors need to pay close attention to CRAI stock based on the movements in the options market lately.